CGRP mAb Subcutaneous denied due to quantity / dose limits by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for cgrp mab subcutaneous are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Applies Quantity Limits to CGRP Monoclonal Antibodies

UnitedHealthcare's quantity-limit denials for subcutaneous CGRP monoclonal antibodies arise when the dispensed quantity — typically measured in units or injection devices per dispensing period — exceeds the amount specified in UHC's coverage policy. These limits reflect the standard dosing regimen described in the FDA-approved labeling, but clinical situations sometimes call for dispensing patterns that fall outside the default quantity. A quantity-limit denial does not mean the drug is not covered; it means the plan will not pay for the volume dispensed on that claim.

## Why This Denial Is Appealable

Quantity-limit denials are adverse benefit determinations carrying full appeal rights under ACA §2719 and ERISA §503. If the clinical record supports a dispensing quantity that differs from the plan's default limit — for example, to accommodate a loading regimen, an authorized titration, or a supply needed before coverage of the next dispensing period — that clinical rationale can be submitted on appeal. The external-review window is typically 4 months from the final internal denial, with an expedited pathway available for urgent situations.

## The Appeal Process

1. Confirm the exact quantity limit applied by reviewing UHC's Coverage Determination Guideline for this drug. 2. Compare the limit to the FDA-approved prescribing information to determine whether the quantity dispensed falls within labeled dosing. 3. If the quantity is within labeled dosing and was denied, the denial may reflect a processing error correctable through a corrected claim or provider billing inquiry. 4. If the quantity genuinely exceeds plan limits for a documented clinical reason, file a written internal appeal with supporting documentation. 5. Escalate to external review if the internal appeal is denied.

## Documentation to Gather

• Prescribing information: The relevant dosing section of the FDA-approved label showing that the dispensed quantity aligns with standard or permitted dosing.
• Prescriber's clinical rationale: A letter explaining why the quantity dispensed was medically necessary (e.g., titration schedule, supply gap, authorized refill cycle).
• Pharmacy dispensing record: Confirming exactly what was dispensed and when.
• Benefit summary excerpt: The plan document section describing quantity-limit exception procedures.

## Criteria-Mapping Structure

Map the exact quantity denied against both the FDA label's dosing guidance and UHC's quantity-limit policy. For each policy requirement for a quantity-limit exception, provide a direct chart or prescriber-letter citation. Keep the appeal focused: quantity-limit appeals are often resolved quickly when the prescriber can show the dispensed quantity is consistent with labeled use and clinical necessity.